Drug
Pralatrexate clinical trials
Also written Folotyn and PDX.
Keep track of what changes. Save the pralatrexate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
34 studies that test it; most in 2010 (8); 1 more planned to start later
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2002 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 8 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 16
Acrotech Biopharma Inc. (12) · Spectrum Pharmaceuticals, Inc (4) · City of Hope Medical Center (2) · University of Virginia (2) · University of Nebraska (2) · Memorial Sloan Kettering Cancer Center (2) · Jennifer Amengual (2) · Mundipharma (China) Pharmaceutical Co. Ltd (1)
Often tested with
Tested in the same studies.
Vitamin B 12 (3) · Folic Acid (3) · Cyclophosphamide (2) · Vincristine (2) · Prednisone (2) · Azacitidine (2) · Romidepsin (2) · Levoleucovorin (2)
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Studies
Open first, then newest update. How each study uses pralatrexate is read from its arms, and is right about nine times in ten.
Testing it · 35
- Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell LymphomaNot yet recruitingPhase 1City of Hope Medical CenterNCT07691450Written as Pralatrexate
- Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin LymphomaRecruitingPhase 1/2Fred Hutchinson Cancer CenterNCT07225985Written as Pralatrexate
- Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic ImpairmentRecruitingPhase 1Acrotech Biopharma Inc.NCT07036133Written as Pralatrexate Injection
- To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCLActive, not recruitingPhase 3Acrotech Biopharma Inc.NCT06072131Written as Pralatrexate Injection
- Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid MalignanciesTerminatedPhase 1/2Jennifer AmengualNCT01947140Written as Pralatrexate
- Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell LymphomasActive, not recruitingPhase 1/2City of Hope Medical CenterNCT03598998Written as Pralatrexate
- Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCLActive, not recruitingPhase 1University of VirginiaNCT03240211Written as Pralatrexate
- Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid TumorsCompletedPhase 1University of NebraskaNCT01206465Written as pralatrexate
- Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin LymphomaCompletedPhase 2University of NebraskaNCT01336933Written as pralatrexate
- Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for LymphomaStatus unknownPhase 1/2University of VirginiaNCT03161223Written as Pralatrexate
- Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma PatientsTerminatedPhase 3Spectrum Pharmaceuticals, IncNCT01420679Written as Pralatrexate Injection
- Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaCompletedPhase 2Spectrum Pharmaceuticals, IncNCT00998946Written as Pralatrexate
- 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's LymphomaCompletedPhase 1/2Spectrum Pharmaceuticals, IncNCT00052442Written as pralatrexate
- A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)CompletedPhase 1Acrotech Biopharma Inc.NCT02594267Written as Pralatrexate Injection
- Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based TreatmentCompletedPhase 2Spectrum Pharmaceuticals, IncNCT00606502Written as Pralatrexate
- Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®WithdrawnPhase 1Acrotech Biopharma Inc.NCT01820091Written as Folotyn
- Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving FolotynWithdrawnPhase 1Acrotech Biopharma Inc.NCT01789723Written as Folotyn
- Study of Pralatrexate in Female Patients With Previously-treated Breast CancerCompletedPhase 2Acrotech Biopharma Inc.NCT01118624Written as Pralatrexate Injection
- Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative MalignanciesCompletedPhase 1/2Acrotech Biopharma Inc.NCT00481871Written as Pralatrexate Injection
- Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell LymphomaCompletedPhase 1Acrotech Biopharma Inc.NCT00554827Written as Pralatrexate
See all 35 studies that test pralatrexate →
As the comparator · 4 — what is tested is compared with pralatrexate
- Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaRecruitingPhase 3Corvus Pharmaceuticals, Inc.NCT06561048Written as Pralatrexate
- Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCLRecruitingPhase 2University of VirginiaNCT04747236Written as Pralatrexate
- KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)CompletedPhase 2Kyowa Kirin, Inc.NCT01626664Written as Pralatrexate
- Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell LymphomaCompletedPhase 3Millennium Pharmaceuticals, Inc.NCT01482962Written as Pralatrexate
Codes
What other systems call pralatrexate · ClinicalTrials.gg INT004294
- UNII (FDA) A8Q8I19Q20PRALATREXATEConfirmed FDA, Wikidata
- RxNorm 662019Confirmed FDA, Wikidata
- Wikidata Q637059pralatrexateConfirmed FDA, Wikidata
- NCI Thesaurus C2250PralatrexateOne source FDA
- DrugBank DB06813One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | A8Q8I19Q20 | PRALATREXATE | Confirmed FDA, Wikidata |
| RxNorm | 662019 | — | Confirmed FDA, Wikidata |
| Wikidata | Q637059 | pralatrexate | Confirmed FDA, Wikidata |
| NCI Thesaurus | C2250 | Pralatrexate | One source FDA |
| DrugBank | DB06813 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.